Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$1.66B, compared with -$1.53B a year earlier.

Context

  • Retained earnings amounted to 2765.4% of total assets at the end of Q1 FY2026, up 984.0 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -8.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.66B-1.9% QoQ
Last fiscal yearDec 2025
-$1.63B-8.2% YoY
Year agoMar 2025
-$1.53B-8.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.0%——
1 year-8.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1.63B) USD
Year-over-year change
-8.2%

Retained Earnings vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -8.0% is the 2nd highest of 11, against a peer median of -16.7%.
  • Retained earnings amounts to 2765.4% of total assets for SGMO, versus a peer median of 391.1%.
SGMO Competitors
Retained Earnings for SGMO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RANIRani Therapeutics Holdings, Inc.Mar 2026-$139.61M USD-26.7%—269.1%
OABIOmniAb, Inc.Mar 2026-$173.89M USD-45.4%—59.2%
MOLNMolecular Partners AGMar 2026-CHF 323.66M CHF-24.1%—370.3%
IMDXInsight Molecular Diagnostics Inc.Mar 2026-$405.05M USD-13.4%—1001.9%
IPHAInnate Pharma S.A.Dec 2025-€435.36M EUR-12.7%—694.4%
MISTMilestone Pharmaceuticals Inc.Mar 2026-$456.67M USD-17.6%—235.7%
CDXSCodexis, Inc.Mar 2026-$615.48M USD-5.5%—475.8%
ARMPArmata Pharmaceuticals, Inc.Mar 2026-$616.88M USD-84.5%—883.8%
CCCCC4 Therapeutics, Inc.Mar 2026-$763.82M USD-15.7%—232.3%
IVVDInvivyd, Inc.Mar 2026-$995.88M USD-8.5%—412.0%
SGMOSangamo Therapeutics, Inc.Mar 2026-$1.66B USD-8.0%—2765.4%
Peer median (excluding SGMO) —-16.7%—391.1%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents178.87M100.44M45.2M41.92M20.95M
Short-term Investments197.68M177.19M35.8M00
Net Receivables6.36M4.47M4.07M4.6M10.51M
Inventory00000
Other Current Assets009.26M5.18M4.37M
Total Current Assets398.77M300.33M94.33M51.69M35.83M
Property, Plant & Equipment (Net)124.7M125.53M52.87M34.76M14.11M
Goodwill39.7M37.55M000
Intangible Assets53.76M50.73M000
Long-term Investments88.17M29.85M1.5M1.5M0
Tax Assets06.27M000
Other Non-current Assets16.82M12.25M16.63M13.69M9.81M
Total Non-current Assets323.15M262.18M70.99M49.94M23.92M
Total Assets721.92M562.51M165.32M101.64M59.75M
Account Payables9.76M22.42M15.26M15.49M14.44M
Short-term Debt00000
Tax Payables0004.07M10.14M
Deferred Revenue85.71M51.78M07.56M899K
Other Current Liabilities20.84M11.89M11.73M14.57M17.72M
Total Current Liabilities127.89M111.71M47.73M45.81M42.47M
Long-term Debt00000
Deferred Tax Liabilities6.65M6.27M000
Deferred Revenue (Non-current)166.78M109.38M05.87M5.87M
Other Non-current Liabilities1.22M1.21M1.19M933K580K
Total Non-current Liabilities218.69M155.84M34.7M33.06M31.55M
Total Liabilities346.58M267.55M82.43M78.87M74.01M
Common Stock1.46M1.67M1.78M2.13M3.51M
Retained Earnings(956.27M)(1.15B)(1.41B)(1.5B)(1.63B)
Accumulated OCI(3.99M)(8.4M)(4.6M)(7.53M)(1.46M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity375.34M294.96M82.89M22.77M(14.27M)
Total Debt48.08M43.11M38.1M30.57M26.8M
Net Debt(130.79M)(57.34M)(7.1M)(11.35M)5.85M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.